Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member
tabling member	label

Search

100186

	registered interest
	date	21/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Patients: Safety
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether missed or inadequate hydrocortisone administration is included in the NHS list of Never Events.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	211233
	answer	answer is ministerial correction date of answer 28/10/2014 answer text <p>Missed or inadequate hydrocortisone administration is not currently included in the list of ‘never events’.</p><p> </p><p> </p><p> </p><p>We can confirm that the current list of Never Events is under review and there is a consultation underway which opened online on the 6 October 2014 and closes on 31 October 2014.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/10/2014 15:28:25 question first ministerially corrected 28/10/2014 16:30:53 answering member 4020 label Biography information for George Freeman previous answer version 24770 answering member constituency Battersea answering member printed Jane Ellison answering member 3918
	tabling member	95 label Biography information for Mr Andrew Smith

171817

	registered interest
	date	02/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what response he has made to the request by NHS England to defer implementation of the guidance on sofosbuvir for hepatitis C.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	219601
	answer	answer is ministerial correction date of answer 09/01/2015 answer text <p>As an independent body, it is for the National Institute for Health and Care Excellence (NICE), in consultation with stakeholders, to consider NHS England’s request to defer implementation of its guidance on sofosbuvir (Sovaldi) for the treatment of chronic hepatitis C.</p><p> </p><p> </p><p> </p><p>NICE recently consulted on extending the funding period and we understand that NICE expects to publish the outcome of that consultation, along with its final draft guidance on sofosbuvir, later this month. The Department’s response to the consultation will be published alongside other stakeholders’ comments. We are confident that NICE will carefully consider all the comments it has received before taking a final decision.</p><p> </p><p> </p><p> </p><p>NICE currently expects to publish its final guidance on sofosbuvir in February 2015, although this is subject to any appeals being received.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 219602 question first answered 09/01/2015 14:33:04 answering member 4020 label Biography information for George Freeman
	tabling member	95 label Biography information for Mr Andrew Smith

171818

	registered interest
	date	02/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when NICE guidance on the use of sofosbuvir for treating hepatitis C will be published.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	219602
	answer	answer is ministerial correction date of answer 09/01/2015 answer text <p>As an independent body, it is for the National Institute for Health and Care Excellence (NICE), in consultation with stakeholders, to consider NHS England’s request to defer implementation of its guidance on sofosbuvir (Sovaldi) for the treatment of chronic hepatitis C.</p><p> </p><p> </p><p> </p><p>NICE recently consulted on extending the funding period and we understand that NICE expects to publish the outcome of that consultation, along with its final draft guidance on sofosbuvir, later this month. The Department’s response to the consultation will be published alongside other stakeholders’ comments. We are confident that NICE will carefully consider all the comments it has received before taking a final decision.</p><p> </p><p> </p><p> </p><p>NICE currently expects to publish its final guidance on sofosbuvir in February 2015, although this is subject to any appeals being received.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 219601 question first answered 09/01/2015 14:33:04 answering member 4020 label Biography information for George Freeman
	tabling member	95 label Biography information for Mr Andrew Smith

178985

	registered interest
	date	10/02/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to his Department's report, Hepatitis C in the UK, published in July 2014, what steps he is taking to approve for use new treatments for people with hepatitis C-related liver damage.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	223984
	answer	answer is ministerial correction date of answer 23/02/2015 answer text <p>The Government is committed to ensuring that patients have access to clinically and cost effective treatments, including those for hepatitis C.</p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the National Health Service on the clinical and cost-effectiveness of health technologies.</p><p> </p><p> </p><p> </p><p>NICE is currently appraising a number of new drugs for use in the treatment of hepatitis C under its technology appraisal process. These are shown in the following table.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Drug/indication</p></td><td><p>Expected date of final guidance</p></td></tr><tr><td><p>sofosbuvir (Sovaldi) for treating chronic hepatitis C</p></td><td><p>February 2015</p></td></tr><tr><td><p>simeprevir (Olysio) for treating genotype 1 or 4 chronic hepatitis C</p></td><td><p>February 2015</p></td></tr><tr><td><p>ledipasvir-sofosbuvir (Harvoni) for treating chronic hepatitis C</p></td><td><p>June 2015</p></td></tr><tr><td><p>daclatasvir (Daklinza) for treating chronic hepatitis C</p></td><td><p>August 2015</p></td></tr><tr><td><p>ombitasvir/paritaprevir/ritonavir (Viekirax) with or without dasabuvir (Exviera) for treating chronic hepatitis C</p></td><td><p>September 2015</p></td></tr></tbody></table><p> </p><p><strong> </strong></p><p> </p><p>More generally, we have launched an Innovative Medicines and Medical Technology Review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p><p> </p><p> </p><p>The review will examine the pathway from ‘first in human’ trials, through licensing and health technology appraisal, to commissioning and clinical practice. It will set out both short and long-term options for action by Government and relevant bodies, including NICE, the Medicines and Healthcare products Regulatory Agency and NHS England, and mark a major contribution to the policy debate.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 23/02/2015 16:20:22 answering member 4020 label Biography information for George Freeman
	tabling member	95 label Biography information for Mr Andrew Smith